Initial trial results for SPVN06 are expected in 2023, with first efficacy data expected in 2025. SparingVision is also developing SPVN20, a second gene therapy drug...
SparingVision has recently closed a financing round during which it managed to raise $52.7 million (€44.5 million). The resources will enable the company to advance the...